MingMed Biotechnology Announces CDE Approval for New Clinical Indication of Recombinant Botulinum Toxin Type A in Adult Upper Limb Spasticity

Jul 05, 2024 10:25 CST Updated 09:59

MingMed

Innovative Drug Developer

▎Edited by the WuXi AppTec content team

On July 5, MingMed announced that its holding company, Chongqing Yuyan Pharmaceutical Co., Ltd., independently developedInjectable Recombinant Botulinum Toxin Type AA new clinical trial application for an additional indication has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.Intended for the treatment of upper limb muscle spasticity in adults。

Screenshot source: CDE official website

According to the press release from MingMed, Chongqing Yuyan Pharmaceutical Co., Ltd.'s recombinant Type A botulinum toxin avoids the biosafety risks associated with traditional production methods without altering protein activity. Combined with its innovative triple-filtration technology, this botulinum toxin offers the advantages of high purity, high specific activity, and a significantly improved response rate.

Previously, theRecombinant Botulinum Toxin Type AApproved by the CDE to conduct clinical trials for the improvement of moderate to severe glabellar lines,Currently, all participants in its Phase 3 clinical trial for the improvement of moderate to severe glabellar lines have completed the study.。

Mr. Liu Miao, Chairman and CEO of Yuyan Pharmaceutical, stated that the clinical approval of YY001-002 marks an important scientific breakthrough for Yuyan Pharmaceutical in the field of serious medical treatment. Developing high-quality drugs through innovative technology to serve patients' health has always been the original intention of Yuyan Pharmaceutical since its establishment. We look forward to Yuyan's recombinant Type A botulinum toxin serving a wide range of patients more quickly.

MingMed focuses on the independent research and development of innovative drugs. Currently, the company has independently developed a diversified and synergistic product pipeline, including recombinant protein botulinum toxin, pet immunization drugs, ophthalmic drugs, and cancer immunotherapy drugs, among which there are several potential "first-in-class" innovative drugs. Chongqing Yuyan Pharmaceutical Co., Ltd., controlled by MingMed Biotechnology Co., Ltd., is a pharmaceutical enterprise dedicated to the R&D, production, and commercialization of botulinum toxin using recombinant protein technology.

References:

[1] World's First | Recombinant Type A Botulinum Toxin Granted Approval for Clinical Trial of Its First Medical Indication. Retrieved July 05，2024. From https://mp.weixin.qq.com/s/xVndN-nP9U-9sqswVB3wvA

This article was compiled and edited by the WuXi AppTec content team based on publicly available information. Feel free to share it on your personal social media feed. For authorization to repost, please leave a message on the "MedView" WeChat Official Account to contact us. For other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.